Impact of Adherence to Antihypertensive Agents on Clinical Outcomes and Hospitalization Costs

Dragomir, Alice; Côté, Robert; Roy, Louise; Blais, Lucie; Lalonde, Lyne; Berard, Aurélie; Perreault, Sylvie

doi:10.1097/mlr.0b013e3181d567bd

Cited by 186 publications

(149 citation statements)

References 34 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…The duration of abiraterone treatment in our study, which was slightly shorter in the postchemotherapy group than in the exception patient group, supports this notion. The median survival in our postchemotherapy group (12.0 [95% CI 11.0-19.0] mo) was slightly less than that observed in the COU-AA-301 trial 3 .0] mo), whereas the latter is similar to the survival in our exception patient group (14.0 [95% CI [11][12][13][14][15][16][17][18][19][20] mo). However, our patients were older than those in the COU-AA-301 trial , and the trial patients may have had a different comorbidity or disease profile, which we were unable to assess.…”

Section: Discussionmentioning

confidence: 61%

Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background: Abiraterone acetate was introduced in Quebec in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who had received chemotherapy with docetaxel. This study describes abiraterone use in the early postapproval period and its clinical effectiveness in Quebec, for both patients who had received docetaxel chemotherapy and those who could not receive docetaxel therapy owing to medical reasons.

show abstract

Section: Discussionmentioning

confidence: 61%

Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even modest nonadherence (e.g., 10-20 %) has been linked with clinically significant deteriorations in health outcomes, such as glycemic control, low-density lipoprotein cholesterol levels, and risk for coronary disease [21,22], as well as failure to achieve health improvements [23], leading to higher healthcare costs [21,24].…”

Section: Defining Medication Adherence Behaviormentioning

confidence: 99%

Self-report measures of medication adherence behavior: recommendations on optimal use

Stirratt

Dunbar‐Jacob

Crane

et al. 2015

Behav. Med. Pract. Policy Res.

591

528

View full text Add to dashboard Cite

Medication adherence plays an important role in optimizing the outcomes of many treatment and preventive regimens in chronic illness. Self-report is the most common method for assessing adherence behavior in research and clinical care, but there are questions about its validity and precision. The NIH Adherence Network assembled a panel of adherence research experts working across various chronic illnesses to review selfreport medication adherence measures and research on their validity. Self-report medication adherence measures vary substantially in their question phrasing, recall periods, and response items. Self-reports tend to overestimate adherence behavior compared with other assessment methods and generally have high specificity but low sensitivity. Most evidence indicates that self-report adherence measures show moderate correspondence to other adherence measures and can significantly predict clinical outcomes. The quality of self-report adherence measures may be enhanced through efforts to use validated scales, assess the proper construct, improve estimation, facilitate recall, reduce social desirability bias, and employ technologic delivery. Self-report medication adherence measures can provide actionable information despite their limitations. They are preferred when speed, efficiency, and low-cost measures are required, as is often the case in clinical care. KeywordsAdherence, Compliance, Self-management, Medication, Self-report Valid measurement of medication adherence plays a crucial role in healthcare and health research. When a patient is not benefiting from a medication regimen, clinicians need sound adherence information to determine whether the medication is ineffective or not being taken as prescribed. Assessing medication adherence during routine clinical care can further ensure that individuals in need of adherence support interventions receive them, ideally before deleterious outcomes occur. In the context of clinical research, proper interpretation of proof-of-concept trials testing new pharmacologic regimens requires valid adherence data, because any null findings may stem from poor adherence rather than a lack of drug efficacy. Research designed to understand and promote medication adherence also requires precise methods of adherence assessment.Among many approaches to assessing medication adherence, patient self-report measures remain the most common method [1][2][3][4][5][6]. These measures are defined by asking respondents to characterize their medication adherence behavior. Self-report measures of medication adherence range from simple singleitem questions regarding missed doses to complex multi-item assessments that incorporate reasons for nonadherence [7]. The widespread use of self-report adherence measures in clinical care and research reflects their low cost and ease of implementation across a large variety of medication regimens.There are two primary challenges related to selfreport measures of medication adherence. ImplicationsPractice: Routine assessment of medication...

show abstract

“…30 Reinforcing measures aimed at improving adherence to treatment is cost effective. 31,32 It has been suggested that the prescription to the whole population older than 55 years of age of a single pill containing a combination of CV drugs (the polypill) could prevent as much as 80% of CVD events 33 and be cost effective. 34 Part of the cost-effectiveness of the polypill is due to improvement in adherence to treatment, but which combination of drugs is most cost effective in which target population remains to be assessed.…”

Section: Cost-effectiveness Of Preventionmentioning

confidence: 99%

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano¹,

Reiner²,

Backer³

et al. 2011

Atherosclerosis

565

189

View full text Add to dashboard Cite

Impact of Adherence to Antihypertensive Agents on Clinical Outcomes and Hospitalization Costs

Abstract: Low adherence to AH agents is correlated with a higher risk of vascular events, hospitalization, and greater healthcare costs. An increased level of adherence to AH agents should provide a better health status for individuals and a net economic gain.

Cited by 186 publications

References 34 publications

Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study

Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study

Self-report measures of medication adherence behavior: recommendations on optimal use

ESC/EAS Guidelines for the management of dyslipidaemias

Contact Info

Product

Resources

About